Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks.

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That ...

In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $60.6 which represents a slight increase of $0.93 or 1.56% from the prior close of $59.67. The stock opened at $60.08 and ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

The ERISA Industry Committee, along with two other industry groups, is seeking the dismissal of the drugmaker’s PRT lawsuit ...